In generic drug plants in China and India, data falsification is still a problem

Stat News

29 October 2019 - As the generic drug industry faces allegations of data manipulation, headlines about carcinogen-tainted blood pressure medicine, and an intensifying probe by the House Energy and Commerce Committee, whose health subcommittee is holding a hearing on Wednesday on safeguarding our global drug supply, generic drug industry lobbyists are fighting back.

They claim that low-cost drug makers operating overseas — where the majority of our generic drugs are made — follow the same intricate rules as U.S. based drug makers. 

They argue that instances of manufacturing fraud or negligent practices are a thing of the past, having ended largely in 2013 when India’s largest drug company, Ranbaxy, pleaded guilty in the United States to seven felonies related to falsifying manufacturing data.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Regulation , Data , China , India